INDIVIDUAL PEPTIDE PROFILE
ACE-031
A soluble fusion protein combining the extracellular domain of the activin receptor type IIB with the Fc portion of a human antibody, engineered to trap myostatin and related muscle-growth-limiting proteins. It was developed by Acceleron Pharma and studied in Duchenne muscular dystrophy before its clinical program was discontinued.
WHAT IT IS
ACE-031 pairs the receptor portion of activin receptor type IIB (ActRIIB) with the Fc region of an antibody. The resulting molecule circulates in the blood and acts as a decoy, binding myostatin and related growth factors such as activin A before they can reach their natural receptor on muscle cells.
It does not occur naturally. It is a laboratory-engineered biologic that was administered by injection in clinical trials and was never sold as an approved medicine or a consumer product.
ACE-031 is best understood today as a case study in myostatin-pathway research rather than an active development candidate. FDA status: ACE-031 is not FDA-approved, and its Duchenne muscular dystrophy development program was discontinued after a Phase II safety signal.
WHAT RESEARCHERS STUDIED IT FOR
Acceleron Pharma's clinical program, along with related preclinical work, examined:
- Preservation of muscle mass and function in boys with Duchenne muscular dystrophy
- The broader myostatin and activin signaling pathway as a target for muscle-wasting conditions
- Effects on lean body mass, fat mass and bone mineral density
- Motor function measures including the 6-minute walk test
PROPOSED BIOLOGICAL MECHANISMS
Myostatin and activin normally bind ActRIIB on muscle cells to restrain fiber growth. ACE-031 was designed to intercept these ligands in circulation, in theory freeing muscle tissue from that restraint and permitting greater growth.
Animal studies had shown that blocking myostatin signaling can produce substantial increases in muscle mass, which is part of why this pathway attracted interest for muscle-wasting diseases.
Because ActRIIB also binds other TGF-beta family ligands beyond myostatin, a non-selective trap like ACE-031 can affect tissues and pathways well beyond skeletal muscle, including blood vessel biology.
AREAS OF RESEARCH INTEREST
- Whether myostatin pathway blockade can improve function, not only muscle mass, in muscle-wasting disease
- Whether more selective agents can preserve any muscle benefit while avoiding vascular side effects
- What role activin A specifically plays in the vascular findings observed with ACE-031
- How findings from this discontinued program inform current myostatin- and activin-pathway drug development
WHAT THE EVIDENCE CURRENTLY SUGGESTS
In a randomized, placebo-controlled Phase II trial in ambulatory boys with Duchenne muscular dystrophy, ACE-031 was not associated with serious or severe adverse events overall, and trends were reported toward increased lean body mass, increased bone mineral density, reduced fat mass and better maintained 6-minute walk test distance compared with placebo.
The study was stopped early after the second dosing regimen because of safety concerns, specifically epistaxis (nosebleeds) and telangiectasia (small dilated blood vessels visible in the skin and gums), seen more often with ACE-031 than placebo.
Acceleron Pharma and its development partner concluded in 2013 that additional toxicology findings did not support restarting the program, and ACE-031 has not returned to active clinical development for Duchenne muscular dystrophy or any other condition.
A cautionary case in muscle-growth research
WHY THIS TRIAL WAS HALTED MATTERS
ACE-031 showed encouraging trends on muscle mass and function measures, but the trial was stopped because of an unexpected pattern of bleeding-related and vascular side effects rather than a lack of apparent benefit.
This distinction, a promising efficacy signal paired with a safety signal serious enough to end the program, is a useful reminder that early positive data and long-term safety are separate questions.
It is also a relevant reference point when evaluating other myostatin- or activin-pathway compounds circulating in research or online marketplaces, since the underlying biology carries similar theoretical risks.
Research Reality Check
What we know
ACE-031 is an ActRIIB-Fc fusion protein that traps myostatin and related growth factors. A randomized Phase II trial in Duchenne muscular dystrophy reported trends toward increased lean mass and maintained walking distance, but was halted early due to epistaxis and telangiectasia, and the program was later discontinued.
What remains uncertain
Whether a more selective activin-pathway approach could preserve muscle benefits without the vascular side effects, and whether the muscle changes observed in the short trial would have translated into meaningful long-term functional benefit for people with Duchenne muscular dystrophy.
Educational commentary, not personal testimonial
The Balanced Body Lifestyle Take
ACE-031 is one of the clearer examples in this field of why an encouraging efficacy trend and a long-term safety profile are two different things. The muscle mass and function signals were real enough to study seriously, but the bleeding and vascular findings were serious enough to end the program.
If ACE-031 or the myostatin pathway more broadly has caught your attention, reach out to us. We can talk through what drew you to it, answer your questions honestly, and look at what current research does and does not show.
QUESTIONS PEOPLE OFTEN ASK
SOURCES & FURTHER READING
- PubMed: Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy, randomized placebo-controlled trial
- ClinicalTrials.gov: Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy (NCT01099761, Terminated)
- Muscular Dystrophy Association: Update on ACE-031 clinical trials in Duchenne MD
- PubMed: Myostatin and activin pathway inhibition in neuromuscular disease, review literature
Peptide Education Consultation
Interested in learning more about peptides? Schedule an educational consultation with Vince Angelo to discuss the information and ask questions.
Schedule an Educational ConsultationEDUCATIONAL NOTICE
The Balanced Body Lifestyle™ provides peptide and wellness information for educational purposes only. Content is intended to help readers better understand emerging research, established evidence and areas of scientific uncertainty. It is not medical advice, diagnosis, treatment guidance or a recommendation to use any medication, peptide or research compound. Decisions involving prescription medications or investigational compounds should be discussed with a qualified healthcare professional.
THE BALANCED BODY LIFESTYLE
A healthy life is built on balance.